

AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

Claims 1-31 (canceled)

32 (Currently Amended). A method of inducing an immune response to a tumor in a subject, which method comprises intradermally or subcutaneously administering total tumor cell RNA to cutaneous cells of the subject *in vivo*, in an amount effective to elicit an immune response against the tumor, wherein the total tumor cell RNA is from tumor cells from the subject, and the immune response reduces or inhibits growth of the tumor.

33 (Previously Presented). The method of claim 32, wherein the tumor is a fibrosarcoma tumor.

34 (Canceled).

35 (Previously Presented). A method for protecting a subject from a cancer, which method comprises intradermally or subcutaneously delivering an immunologically effective amount of total tumor cell RNA to cutaneous cells of the subject *in vivo*, wherein the total tumor cell RNA is taken from an autologous tumor associated with the cancer.

36 (Previously Presented). The method of claim 35, further comprising delivering an immunostimulatory amount of an immune activating or inflammatory cytokine to the subject.

Claims 37- 42 (Canceled).

43 (Currently Amended). A method of inducing immune tolerance to an allogenic transplant tissue antigen in a subject, which method comprises intravenously administering RNA from cells which ~~comprise~~ comprises allogenic transplant tissue antigen RNA to the subject in an amount effective to elicit immune tolerance against the allogenic transplant tissue antigen, wherein the RNA is administered prior to allogenic transplantation ~~wherein the antigen is an allogenic transplant tissue antigen.~~

44 (Currently Amended). The method of claim 43, wherein the RNA is total cellular RNA from tissues containing the allogenic transplant tissue antigen.

45 (Currently Amended). The method of claim 43, wherein the RNA is total cellular mRNA from tissues containing the allogenic transplant tissue antigen.

46 (Currently Amended). The method of claim 43, wherein the RNA is mRNA encoding the allogenic transplant tissue antigen.

Claims 47-49 (Canceled).

50 (Currently Amended). The method of claim 43, wherein tolerance is induced to ~~the transplant tissue antigen~~ tissue from an organ or blood cells.

51 (Currently Amended). The method of claim 43, wherein tolerance is induced to ~~the transplant tissue antigen~~ is skin tissue.

52 (Currently Amended). The method of claim 43, wherein tolerance is induced to ~~the transplant tissue~~ is tissue from a heart, lung, liver, kidney, or pancreas.

53 (Currently Amended). The method of claim 43, wherein tolerance is induced to ~~the transplant tissue~~ is from platelets, lymphocytes, leukocytes, or red blood cells.

54. (New) The method of claim 44, wherein the RNA is from cells of the allogenic transplant tissue.

55. (New) The method of claim 45, wherein the RNA is from cells of the allogenic transplant tissue.

56. (New) The method of claim 44, wherein the RNA is from spleen cells.

57. (New) The method of claim 45, wherein the RNA is from spleen cells.